Witty Health Announces the Launch of Cancer Drug Utilization Tool for Oncologists on OncoPower, a Digital Health Platform
HOUSTON, Nov. 26, 2018
HOUSTON, Nov. 26, 2018 /PRNewswire-PRWeb/ -- Witty Health Inc., an oncology-focused digital health- blockchain company has announced the launch of first of its kind Cancer Drug Utilization Tool on OncoPower, an oncologist-designed platform that utilizes digital health and professional networking to improve cancer care and precision medicine.
OncoPower helps oncologists create a de-identified case study with details like co-morbidity, specific cancer type, lines of therapy, and actual drugs used for treatment. It then rates the effectiveness of those drugs and publishes the data on the fly in minutes. The purpose of the tool is to assess if drugs safely and effectively improve a patient's health status with a specific cancer and stage. As more data is gathered, a Peer Compare tool enables community oncologists to compare their proposed treatment plans for a particular patient with their peer's practice preferences with several variables: gender, age, co-morbidity, primary cancer site, specific cancer, stage, lines of therapy, prior treatment, and drug.
"As we continue to advance the development of OncoPower digital health ecosystem, we are pleased to enable oncology providers to publish their specific case studies and rate the effectiveness of drugs benefiting everyone– patients, oncologists, drug discoverers, and pharmacists in the cancer care value chain," said Witty Health Co-Founder and Chief Oncologist, Karthik Koduru MD. "The OncoPower drug rating differs from other methods used to rate drugs because it is based on their use in a real world clinical case. This drug rating aims to improve efficiency, delivery of care, and outcomes by providing patient specific and data-driven smart treatment options to Oncologists."
When the platform feature is fully built, OncoPower will be powered by a blockchain-integrated, digitally generated security called Onco, a class B non-voting security that will power all platform actions and serve as the fuel of the incentivized oncology market. With OncoPower, participants are both shareholders and users. They retain both the clinical and social benefits, as well as most of the financial benefits, via Onco distributed using transparent consensus algorithms.
"With an estimated 1.7 million new cancer diagnoses expected this year alone, Oncologists need all the help from artificial intelligence, digital health, and patient engagement tools to improve cancer care. The best part of the OncoPower platform is that its development is completely ground up with direct inputs from the practicing oncologists who see several hundred cancer patients every month and it is led by a team of Oncologists who know what is best for the patients," stated Dr. Amitkumar Mehta, a medical oncologist and hematologist at the University of Alabama School of Medicine, Birmingham, AL.
OncoPower is an oncologist-designed platform developed to create value for the global cancer community. It is HIPAA-compliant and uses integrated clinical care and social determinants of health (SDoH) approach. It includes two other digital health tools: SmartCTP™–, a Smart cancer treatment platform to monitor patients remotely; and SmartOnc™–, an inter-professional consult tool to facilitate peer-to-peer consultations. Both SmartCTP™ and SmartOnc™ comply with the CPT® codes proposed by CMS for reimbursements starting in January 2019. OncoPower was developed by Witty Health, Inc., a Houston-based technology company focused on real-time health risk monitoring solutions to improve cancer care. According to IMS and Global Research, global oncology market participants are projected to spend $150 billion on medications and $120 billion on diagnostics by 2020. CPT® codes are the trademarks of American Medical Association.
SOURCE Witty Health